| NCT ID | NCT06820515 |
| Status | Recruiting |
| Phase | — |
| Sponsor | American Thrombosis and Hemostasis Network |
| Condition | Hemophilia |
| Study Type | OBSERVATIONAL |
| Enrollment | 200,000 participants |
| Start Date | 2024-10-25 |
| Primary Completion | 2054-10-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200,000 participants in total. It began in 2024-10-25 with a primary completion date of 2054-10-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.
Eligibility Criteria
Inclusion Criteria: * Any participant evaluated for or the potential to have a blood disorder who has an encounter with an ATHN Affiliate. * Participants of any age. * Participant is able to provide consent or assent; a Legally Authorized Representative (LAR) may provide consent on a participant's behalf if a participant is unable to provide self-consent Exclusion Criteria: * Any participant unable to provide consent or assent to participate in the ATHNdataset
Contact & Investigator
Tammuella Chrisentery-Singleton, M.D.
PRINCIPAL INVESTIGATOR
American Thrombosis and Hemostasis Network
Frequently Asked Questions
Who can join the NCT06820515 clinical trial?
This trial is open to participants of all sexes, studying Hemophilia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06820515 currently recruiting?
Yes, NCT06820515 is actively recruiting participants. Contact the research team at ecallegari@athn.org for enrollment information.
Where is the NCT06820515 trial being conducted?
This trial is being conducted at Hickory, United States.
Who is sponsoring the NCT06820515 clinical trial?
NCT06820515 is sponsored by American Thrombosis and Hemostasis Network. The principal investigator is Tammuella Chrisentery-Singleton, M.D. at American Thrombosis and Hemostasis Network. The trial plans to enroll 200,000 participants.